Information For Healthcare Professionals

Patients are still developing severe mpox. A March 3, 2023, MMWR provides updated clinical treatment considerations about using therapeutics to treat severe mpox cases, including ocular infections, neurologic complications, myopericarditis, complications associated with mucosal lesions, and complications from uncontrolled viral spread.

Interim Clinical Considerations for Mpox Vaccination

CDC has updated its Interim Clinical Considerations for using the JYNNEOS and ACAM2000 vaccines during the 2022 U.S. mpox outbreak, including an alternative regimen for administering the JYNNEOS vaccine intradermally.

Caring for Patients
Key Characteristics for Identifying Mpox

CDC urges healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox.

Prevent and Control Mpox
Vaccine Information

When properly administered before an exposure, vaccines are effective at protecting people against mpox.